Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02019472 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis
A Phase 3 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 559
- Enrollment target
NCT02019472 is a Phase 3 study that has completed, run by Janssen Research & Development. The registered enrollment target is 559 participants.
The verdict
NCT02019472, a Phase 3 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 559 participants
- Enrollment target
Study Summary
The primary objective is to investigate the efficacy of sirukumab monotherapy compared with adalimumab monotherapy in biologic naïve subjects with active rheumatoid arthritis who are intolerant to methotrexate, who are considered inappropriate for treatment with methotrexate or who are inadequate responders to methotrexate.
Interventions
- DRUG Placebo
- BIOLOGICAL adalimumab 40 mg
- BIOLOGICAL sirukumab 100 mg
- BIOLOGICAL sirukumab 50 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 559 participants |
| Start Date | 2014-04-04 |
| Est. Completion | 2016-08-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02019472
The ClinicalTrials.gov registry entry for NCT02019472 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 559 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02019472 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02019472 about?
NCT02019472 is a clinical study titled "A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis". The primary objective is to investigate the efficacy of sirukumab monotherapy compared with adalimumab monotherapy in biologic naïve subjects with active rheumatoid arthritis who are intolerant to methotrexate, who are considered inappropriate for treatment with methotrexate or who are inadequate re...
What is the current status of trial NCT02019472?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 559 participants. The study started on 2014-04-04. Estimated completion is 2016-08-17.
What interventions are being tested in trial NCT02019472?
The interventions under investigation include: Placebo (DRUG), adalimumab 40 mg (BIOLOGICAL), sirukumab 100 mg (BIOLOGICAL), sirukumab 50 mg (BIOLOGICAL).
Who is sponsoring clinical trial NCT02019472?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.